Navigation Links
Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
Date:9/5/2007

HAYWARD, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and CEO, will present at the Bear Stearns 20th Annual Healthcare Conference in New York at the Grand Hyatt on Monday, September 10, 2007 at 10:30 a.m. Eastern Time. A live webcast of the presentation can be accessed through http://cc.talkpoint.com/BEAR002/091007a_sc/?entity=kosan.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... York , May 4, 2016 ... Transparency Market Research "Metabolomics Market - Global Industry Analysis, ... the metabolomics market is anticipated to expand at a ... USD 2,494.8 million by 2024. Metabolomics is ... metabolites, within cells, biofluids, tissues or organisms. Together, these ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... innovations in biotechnology to help treat hormonal and stress related hair loss. With ... captured the hearts of key opinion leaders in the medical and salon channels ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today ... course: Overview of Regulatory Requirements for Medical Devices. The course is essential for ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, ... and June 1st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
Breaking Biology News(10 mins):